Inactivation of the Pseudomonas-Derived Cephalosporinase-3 (PDC-3) by Relebactam [PublishAheadOfPrint]

Pseudomonas aeruginosa is a prevalent and life-threatening Gram-negative pathogen acquired predominantly by immunosuppressed patients during hospitalization. Relebactam, a diazabicyclooctane β-lactamase inhibitor, potently inactivates the Pseudomonas-Derived Cephalosporinase (PDC-3) with a k₂/K of 41,400 M^-1s^-1 and a k_off of 0.00095 s^-1. Relebactam restored susceptibility to imipenem in 62% of multidrug-resistant (MDR) P. aeruginosa clinical isolates, while only 21% of isolates were susceptible to imipenem-cilastatin alone. Relebactam promises to increase the efficacy of imipenem-cilastatin against P. aeruginosa.

http://ift.tt/2FDK68b